Clinical Trials Browser

Phase 2 × tocilizumab × Plasma cell × Clear all

NCT05972135 2026-02-23

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Phase 2 Recruiting

Cytokine Release Syndrome, Multiple Myeloma